147 related articles for article (PubMed ID: 10826900)
1. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.
Larsen CS; Ostergård L; Møller BK; Buhl MR
Scand J Infect Dis; 2000; 32(2):153-60. PubMed ID: 10826900
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808
[TBL] [Abstract][Full Text] [Related]
3. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
[TBL] [Abstract][Full Text] [Related]
5. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.
Lombardi VR; García M; Rey L; Cacabelos R
J Neuroimmunol; 1999 Jun; 97(1-2):163-71. PubMed ID: 10408971
[TBL] [Abstract][Full Text] [Related]
8. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
9. Different meaning of CD38 molecule expression on CD4+ and CD8+ cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years.
de Martino M; Rossi ME; Azzari C; Gelli MG; Galli L; Vierucci A
Pediatr Res; 1998 Jun; 43(6):752-8. PubMed ID: 9621984
[TBL] [Abstract][Full Text] [Related]
10. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
11. Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls.
Lenkei R; Bratt G; Holmberg V; Muirhead K; Sandström E
Cytometry; 1998 Oct; 33(2):115-22. PubMed ID: 9773871
[TBL] [Abstract][Full Text] [Related]
12. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion.
Gascon RL; Narváez AB; Zhang R; Kahn JO; Hecht FM; Herndier BG; McGrath MS
J Acquir Immune Defic Syndr; 2002 Jun; 30(2):146-53. PubMed ID: 12045676
[TBL] [Abstract][Full Text] [Related]
13. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.
Orendi JM; Bloem AC; Borleffs JC; Wijnholds FJ; de Vos NM; Nottet HS; Visser MR; Snippe H; Verhoef J; Boucher CA
J Infect Dis; 1998 Nov; 178(5):1279-87. PubMed ID: 9780247
[TBL] [Abstract][Full Text] [Related]
14. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.
Kestens L; Vanham G; Vereecken C; Vandenbruaene M; Vercauteren G; Colebunders RL; Gigase PL
Clin Exp Immunol; 1994 Mar; 95(3):436-41. PubMed ID: 7907956
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Meroni L; Manganaro D; Varchetta S; Gatti N; Riva A; Monforte AD; Galli M
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):401-3. PubMed ID: 11707681
[No Abstract] [Full Text] [Related]
16. 'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses.
Lederman MM; Kalish LA; Asmuth D; Fiebig E; Mileno M; Busch MP
AIDS; 2000 May; 14(8):951-8. PubMed ID: 10853976
[TBL] [Abstract][Full Text] [Related]
17. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
18. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
19. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study.
Giorgi JV; Liu Z; Hultin LE; Cumberland WG; Hennessey K; Detels R
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):904-12. PubMed ID: 7686224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
